Jasmiel Kit
Product Images NDC 50102-240

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Jasmiel (NDC 50102-240). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Afaxys Pharma, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Drospirenone Fig1)

The text appears to be a chart or a figure that lists various studies and their respective hazard ratios or odds ratios related to VTE risk associated with the use of Yasmin in comparison to other LNG-containing COCs. It includes some adjustment factors and explains that risk ratios less than 1 indicate a lower risk of VTE with DRSP, whereas ratios greater than 1 indicate a higher risk. The references for the studies are provided at the end.*

FDA Label Image

Figure 2 (Drospirenone Fig2)

This is a description of a chart that indicates the likelihood of developing a VIE (vascular intravascular event) for non-pregnant persons who are not using contraceptive pills. The chart shows the number of women with a blood clot out of 10,000 women years for postpartum women (12 weeks only) and non-pregnant women who are not using COC (contraceptive oral contraceptive pill). The pregnancy data used for this chart is based on the actual duration of pregnancy in the reference studies, and the assumption that pregnancy duration is nine months. The VIE rate is between 7 to 27 per 10,000 WY.*

FDA Label Image

Figure3 (Drospirenone Fig3)

This text provides a summary of various studies that have investigated the association between the use of combined oral contraceptives (COCs) and certain health outcomes. The studies compare the risk of health outcomes for women who have either ever used COCs or those who have never used them, as well as the risk for current COC users compared to never-users. The text presents effect estimates, reported as odds ratios (OR) and risk ratios (RR), for each study. However, it is not specified what health outcomes are being studied, and some important context or interpretation of the effect estimates is missing.*

FDA Label Image

Figure4 (Drospirenone Fig4)

This text describes different methods of contraception and their effectiveness in preventing pregnancy. It provides information on the number of pregnancies per 100 women in one year for each method of contraception, ranging from less than 1 for highly effective methods such as implants and sterilization, to 85 or more for no birth control. The different methods discussed include hormonal options such as birth control pills and injections, barrier methods such as condoms and diaphragms, and behavioral methods such as tracking fertile days and using spermicide.*

FDA Label Image

Figure5 (Drospirenone Fig5)

FDA Label Image

Figure6 (Drospirenone Fig6)

This is a chart showing the ranges of blood clot incidents per 10,000 women years in different situations. The situations include non-pregnant, non-COC user, COC user, and postpartum (12 weeks only). The number of women with a blood clot is shown for each situation. It notes that the pregnancy data is based on actual pregnancy duration and the rate of blood clot incidents during pregnancy is between 7 to 27 per 10,000 women years.*

FDA Label Image

Figure7 (Drospirenone Fig7)

Jasmiel is a birth control product that comes in a blister pack of 28 tablets. The product contains Drospirenone and Ethinyl Estradiol, and is a combination tablet. The provided text also contains references to a pharmacy named "SAXRJR" that may carry the product, but the readability of the text is low.*

FDA Label Image

Drospirenone Fig8

This is a description for Jasmiel® oral contraceptive medication. The package contains 3 pouches and each pouch contains 1 blister pack of 28 tablets. The usual dosage of the tablet is one tablet daily for 28 consecutive days. The tablet is not intended to protect against sexually transmitted infections such as HIV or AIDS. The package has labeling and dosage information and should be stored at room temperature between 20°C and 25°C in a USP controlled room.*

FDA Label Image

Chemical Str (Drospirenone Str)

Drospirenone and Ethinyl Estradiol are two hormonal contraceptives often used together in birth control pills. Drospirenone is a progestin hormone and ethinyl estradiol is an estrogen hormone. These hormones work to prevent pregnancy by stopping ovulation, thickening the cervical mucus, and making it difficult for sperm to reach an egg. It is important to note that these birth control pills do not protect against sexually transmitted infections (STIs).*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.